Ciforadenant (, ; developmental code names CPI-444 and V-81444) is an adenosine A2A receptor antagonist which is under development for the treatment of renal cell carcinoma and non-small cell lung cancer. It is or was also under development for the treatment of attention-deficit hyperactivity disorder (ADHD), cancer, multiple myeloma, Parkinson's disease, and solid tumors, but no recent development has been reported for these indications. The drug is taken orally.
It shows high affinity for the adenosine A2A receptor (Ki = 3.54nM) and high selectivity for this receptor over the other adenosine receptors (54- to 693-fold). The elimination half-life of ciforadenant is 3hours with a single dose and 10.2 to 10.6hours with multiple repeated doses in humans.
Ciforadenant was originated by Vernalis and is under development by Corvus Pharmaceuticals. As of January 2026, it is in phase 2 clinical trials for renal cell carcinoma and phase 1/2 trials for non-small cell lung cancer, whereas there has been no recent development for other uses.
See also List of investigational attention deficit hyperactivity disorder drugs List of investigational Parkinson's disease drugs
References